Author:
Moreau P,Joshua D,Chng W-J,Palumbo A,Goldschmidt H,Hájek R,Facon T,Ludwig H,Pour L,Niesvizky R,Oriol A,Rosiñol L,Suvorov A,Gaidano G,Pika T,Weisel K,Goranova-Marinova V,Gillenwater H H,Mohamed N,Aggarwal S,Feng S,Dimopoulos M A
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference21 articles.
1. van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37: 266–283.
2. National Comprehensive Cancer Network. NCCN Guidelines Multiple Myeloma (Version 2.2016). [cited October 2015]; Available from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp .
3. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M . Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia 2012; 26: 73–85.
4. Kurtin SE . Relapsed or relapsed/refractory multiple myeloma. J Adv Pract Oncol 2013; 4: 5–14.
5. Durie BG, Moreau P, Sonneveld P, Morgan GJ, Lahuerta JJ, Beksac M et al. Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol 2012; 30: (suppl; abstr 8095).